The SCARDA-funded Nipah vaccine candidate (MV-NiV) is a live attenuated measles vector-based vaccine containing the Nipah virus G gene (Malaysia strain). MV-NiV was developed at The Institute of Medical Science, University of Tokyo, and was shown to induce humoral and cellular immune responses and to protect against a lethal Nipah virus infection in preclinical studies. Process development and manufacturing is underway at Batavia Biosciences. Once this is completed, a first-in-human study in healthy non-exposed volunteers is planned to assess the safety and immunogenicity of MV-NiV.